PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 321-337

  Gravina, Giovanni Luca ^a,b,f   Marampon, Francesco ^a,b   Muzi, Paola ^c   Mancini, Andrea ^d   Piccolella, Margherita ^e   Negri Cesi, Paola ^e   Motta, Marcella ^e   Lenzi, Andrea ^f   Cesare, Ernesto Di ^a,b   Tombolini, Vincenzo ^g   Jannini, Emmanuele A ^d   Festuccia, Claudio ^a,b  

^a Department of Experimental Medicine   (Italy)

^b Division of Radiotherapy   (Italy)

^c General Pathology ^*  (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g POLICLINICO UMBERTO I   (Italy)

Author keywords

Androgen receptor; Epigenetic; Histone deacetylase; Hormone refractory prostate cancer; PXD101

Indexed keywords

ANDROGEN RECEPTOR; BELINOSTAT; BICALUTAMIDE; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXPORTIN 1; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE B; SURVIVIN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SIZE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANDROGEN RECEPTOR; EPIGENETIC; HISTONE DEACETYLASE; HORMONE REFRACTORY PROSTATE CANCER; PXD101;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CASTRATION; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; KARYOPHERINS; MALE; MICE; MICE, NUDE; NITRILES; PHENOTYPE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES; TOSYL COMPOUNDS;

EID: 84879496227     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0240     Document Type: Article

References (38)

1. Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federicu G & Bernardini S 2006 Valproic acid induces apoptosis in prostate cancer cell lines by activation of multiple death pathways. Anti-Cancer Drugs 17 1141-1150. (doi:10.1097/01.cad. 0000236302.89843.fc)
2. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P et al. 2005 Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. Journal of Biological Chemistry 280 26729-26734. (doi:10.1074/jbc.C500186200)
3. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P et al. 2008 SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinasedependent cancers. Clinical Cancer Research 14 240-248. (doi:10.1158/1078-0432.CCR-07- 1667)
4. Chen L, Mooso B, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL et al. 2011 Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clinical Cancer Research 17 6218-6228. (doi:10.1158/1078-0432.CCR-11-1548)
5. Chou YW, Chaturvedi NK, Ouyang S, Lin FF, Kaushik D, Wang J, Kim I & Lin MF 2011 Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Letters 311 177-186. (doi:10.1016/j.canlet.2011.07.015)
6. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, Vicentini C & Bologna M 2007 Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocrine-Related Cancer 14 601-611. (doi:10.1677/ERC-07-0118)
7. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W & Verdin E 2002 Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Molecular Cell 9 45-57. (doi:10.1016/S1097-2765(01)00429-4)
8. Frigo DE & McDonnell DP 2008 Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Molecular Cancer Therapeutics 7 659-669. (doi:10.1158/1535-7163.MCT-07-0480)
9. Frønsdal K, Saatcioglu F, Chou YW, Chaturvedi NK, Ouyang S, Lin FF, Kaushik D & Wang J 2005 Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 62 299-306. (doi:10.1002/pros.20140)
10. Gibbs A, Schwartzman J, Deng V & Alumkal J 2009 Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. PNAS 106 16663-16668. (doi:10.1073/pnas.0908908106)
11. Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto R, Dolo V, Tombolini V, Jannini EA & Festuccia C 2011a Differential effects of PXD101 (Belinostat) on androgen dependent and androgen independent prostate cancer models. International Journal of Oncology 40 711-720.
12. Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V et al. 2011b Hormone treatment promotes castration resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology 152 4550-4561. (doi:10.1210/en.2011-1056)
13. Halkidou K, Cook S, Leung HY, Neal DE & Robson CN 2004a Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. European Urology 45 382-389. (doi:10.1016/j.eururo.2003.10.005)
14. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE & Robson CN 2004b Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59 177-189. (doi:10.1002/pros. 20022)
15. Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A & Wikström P 2011 Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6 e19059. (doi:10.1371/journal.pone. 0019059)
16. Karan D, Kelly DL, Rizzino A, Lin MF & Batra SK 2002 Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23 967-975. (doi:10.1093/carcin/23.6.967)
17. Kokontis J, Ito K, Hiipakka RA & Liao S 1991 Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor 1 271-279.
18. Kokontis JM, Hay N & Liao S 1998 Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Molecular Endocrinology 12 941-953. (doi:10.1210/me.12.7.941)
19. Kong L, Yuan Q, Zhu H, Li Y, Guo Q, Wang Q, Bi X & Gao X 2011 The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials 32 6515-6522. (doi:10.1016/j.biomaterials.2011.05.032)
20. Korkmaz CG, Frønsdal K, Zhang Y, Lorenzo PI & Saatcioglu F 2004 Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation - rescue of transcriptionally compromised mutants. Journal of Endocrinology 182 377-389. (doi:10.1677/joe.0.1820377)
21. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB & Yao TP 2005 HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Molecular Cell 18 601-607. (doi:10.1016/j.molcel.2005.04.021)
22. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD & Keller ET 2001 Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47 212-221. (doi:10.1002/pros. 1065)
23. Lonergan PE & Tindall DJ 2011 Androgen receptor signaling in prostate cancer development and progression. Journal of Carcinogenesis 10 20. (doi:10.4103/1477-3163.83937)
24. Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM & Jenster G 2011 Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS ONE 6 e23144. (doi:10.1371/journal.pone.0023144)
25. Patra SK, Patra A & Dahiya R 2001 Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochemical and Biophysical Research Communications 287 705-713. (doi:10.1006/bbrc. 2001.5639)
26. Perry AS, Watson RW, Lawler M & Hollywood D 2010 The epigenome as a therapeutic target in prostate cancer. Nature Reviews. Urology 7 668-680. (doi:10.1038/nrurol.2010.185)
27. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB & Brown R 2003 Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Molecular Cancer Therapeutics 2 721-728.
28. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS & Jeffers M 2006 Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Molecular Cancer Therapeutics 5 2086-2095. (doi:10.1158/1535-7163. MCT-06-0111)
29. Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS & Jeffers M 2008 Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. International Journal of Cancer 122 1400-1410. (doi:10.1002/ijc.23243)
30. Saporita AJ, Ai J & Wang Z 2007 The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67 509-520. (doi:10.1002/pros. 20541)
31. Schütz SV, Cronauer MV & Rinnab L 2010 Inhibition of glycogen synthase kinase-3β promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. Journal of Cellular Biochemistry 109 1192-1200. (doi:10.1002/jcb.22500)
32. Sharifi N 2010 New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opinion on Investigational Drugs 19 837-846. (doi:10.1517/13543784.2010.494178)
33. Shiota M, Yokomizo A, Fujimoto N & Naito S 2011 Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castrationresistant prostate cancer. Current Cancer Drug Targets 11 870-881.
34. Wang D & Tindall DJ 2011 Androgen action during prostate carcinogenesis. Methods in Molecular Biology 776 25-44. (doi:10.1007/978-1- 61779-243-4-2)
35. Wang LG, Ossowski L & Ferrari AC 2001 Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Research 61 7544-7551.
36. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N & Sawyers CL 2009 Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research 69 958-966. (doi:10.1158/0008-5472.CAN-08-2216)
37. Zhao H, Dupont J, Yakar S, Karas M & LeRoith D 2004 PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23 786-794. (doi:10.1038/sj.onc. 1207162)
38. Zhou F, Zhao W, Zuo Z, Sheng Y, Zhou X, Hou Y, Cheng H & Zhou R 2010 Characterization of androgen receptor structure and nucleocytoplasmic shuttling of the rice field eel. Journal of Biological Chemistry 285 37030-37040. (doi:10.1074/jbc.M110.161968)